Programs established by FDA to expedite patient access to medications.
Motl
Susannah
S
Drug Information Center, University of Tennessee Health Science Center, 875 Monroe Avenue, Suite 116, Memphis, TN 38163, USA. smotl@utmem.edu
Miller
Sarah J
SJ
Burns
Patrick
P
D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D017277:Drug Approval; D004345:Drug Industry; D011307:Drug Prescriptions / Q000191:economics; D004335:Drug and Narcotic Control; D006297:Health Services Accessibility / Q000458:organization & administration*; D006801:Humans; D000068877:Imatinib Mesylate; D009965:Orphan Drug Production; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate